| Efficacy and safety of tenecteplase in combination with enoxaparin, abciximab, or unfractionated heparin: the ASSENT-3 randomised trial in acute myocardial infarction TA of the Safety The Lancet 358 (9282), 605-613, 2001 | 400 | 2001 |
| International guidelines on radiation therapy for breast cancer during the COVID-19 pandemic CE Coles, C Aristei, J Bliss, L Boersma, AM Brunt, S Chatterjee, G Hanna, ... Clinical Oncology 32 (5), 279-281, 2020 | 257 | 2020 |
| UK consensus on normal tissue dose constraints for stereotactic radiotherapy GG Hanna, L Murray, R Patel, S Jain, KL Aitken, KN Franks, N Van As, ... Clinical Oncology 30 (1), 5-14, 2018 | 244 | 2018 |
| Nivolumab versus placebo in patients with relapsed malignant mesothelioma (CONFIRM): a multicentre, double-blind, randomised, phase 3 trial DA Fennell, S Ewings, C Ottensmeier, R Califano, GG Hanna, K Hill, ... The Lancet Oncology 22 (11), 1530-1540, 2021 | 197* | 2021 |
| PET/CT imaging for target volume delineation in curative intent radiotherapy of non-small cell lung cancer: IAEA consensus report 2014 T Konert, W Vogel, MP MacManus, U Nestle, J Belderbos, V Grégoire, ... Radiotherapy and Oncology 116 (1), 27-34, 2015 | 156 | 2015 |
| Geometrical analysis of radiotherapy target volume delineation: a systematic review of reported comparison methods GG Hanna, AR Hounsell, JM O’Sullivan Clinical oncology 22 (7), 515-525, 2010 | 130 | 2010 |
| Motion management for radical radiotherapy in non-small cell lung cancer AJ Cole, GG Hanna, S Jain, JM O'Sullivan Clinical oncology 26 (2), 67-80, 2014 | 85 | 2014 |
| A systematic review of outcomes following stereotactic ablative radiotherapy in the treatment of early-stage primary lung cancer P Murray, K Franks, GG Hanna The British journal of radiology 90 (1071), 20160732, 2017 | 81 | 2017 |
| Improving target delineation on 4-dimensional CT scans in stage I NSCLC using a deformable registration tool IE van Dam, JRS de Koste, GG Hanna, R Muirhead, BJ Slotman, S Senan Radiotherapy and oncology 96 (1), 67-72, 2010 | 66 | 2010 |
| 18f-fdg pet-ct simulation for non–small-cell lung cancer: effect in patients already staged by pet-ct GG Hanna, J McAleese, KJ Carson, DP Stewart, VP Cosgrove, RL Eakin, ... International Journal of Radiation Oncology* Biology* Physics 77 (1), 24-30, 2010 | 65 | 2010 |
| Study protocol for the SARON trial: a multicentre, randomised controlled phase III trial comparing the addition of stereotactic ablative radiotherapy and radical radiotherapy … J Conibear, B Chia, Y Ngai, AT Bates, N Counsell, R Patel, D Eaton, ... BMJ open 8 (4), e020690, 2018 | 61 | 2018 |
| The abscopal effect of stereotactic radiotherapy and immunotherapy: Fool's gold or El Dorado? D Xing, S Siva, GG Hanna Clinical oncology 31 (7), 432-443, 2019 | 59 | 2019 |
| Immune modulation in advanced radiotherapies: targeting out-of-field effects GG Hanna, VM Coyle, KM Prise Cancer letters 368 (2), 246-251, 2015 | 56 | 2015 |
| UK 2022 consensus on normal tissue dose-volume constraints for oligometastatic, primary lung and hepatocellular carcinoma stereotactic ablative radiotherapy P Diez, GG Hanna, KL Aitken, N Van As, A Carver, RJ Colaco, J Conibear, ... Clinical Oncology 34 (5), 288-300, 2022 | 50 | 2022 |
| CONFIRM: a double-blind, placebo-controlled phase III clinical trial investigating the effect of nivolumab in patients with relapsed mesothelioma: study protocol for a … DA Fennell, E Kirkpatrick, K Cozens, M Nye, J Lester, G Hanna, N Steele, ... Trials 19, 1-10, 2018 | 49 | 2018 |
| Image-guided radiotherapy to manage respiratory motion: lung and liver J Dhont, SV Harden, LYS Chee, K Aitken, GG Hanna, J Bertholet Clinical oncology 32 (12), 792-804, 2020 | 48 | 2020 |
| Protocol for the isotoxic intensity modulated radiotherapy (IMRT) in stage III non-small cell lung cancer (NSCLC): a feasibility study K Haslett, K Franks, GG Hanna, S Harden, M Hatton, S Harrow, ... BMJ open 6 (4), e010457, 2016 | 41 | 2016 |
| Inhibition of ataxia telangiectasia related-3 (ATR) improves therapeutic index in preclinical models of non-small cell lung cancer (NSCLC) radiotherapy V Dunne, M Ghita, DM Small, CBM Coffey, S Weldon, CC Taggart, ... Radiotherapy and Oncology 124 (3), 475-481, 2017 | 36 | 2017 |
| Stereotactic body radiotherapy for oligometastatic disease GG Hanna, D Landau Clinical Oncology 27 (5), 290-297, 2015 | 33 | 2015 |
| FLIP: A targetable mediator of resistance to radiation in non–small cell lung cancer KA McLaughlin, Z Nemeth, CA Bradley, L Humphreys, I Stasik, C Fenning, ... Molecular cancer therapeutics 15 (10), 2432-2441, 2016 | 31 | 2016 |
fiona mcdonaldRoyal Marsden HospitalVerified email at rmh.nhs.uk
